Cell & Bioscience (Jun 2021)

ADP-ribosyltransferase PARP11 suppresses Zika virus in synergy with PARP12

  • Lili Li,
  • Yueyue Shi,
  • Sirui Li,
  • Junxiao Liu,
  • Shulong Zu,
  • Xin Xu,
  • Meiling Gao,
  • Nina Sun,
  • Chaohu Pan,
  • Linan Peng,
  • Heng Yang,
  • Genhong Cheng

DOI
https://doi.org/10.1186/s13578-021-00628-y
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 13

Abstract

Read online

Abstract Background Zika virus (ZIKV) infection and ZIKV epidemic have been continuously spreading silently throughout the world and its associated microcephaly and other serious congenital neurological complications poses a significant global threat to public health. Type I interferon response to ZIKV infection in host cells suppresses viral replication by inducing the expression of interferon-stimulated genes (ISGs). Methods The study aims to demonstrate the anti-ZIKV mechanism of PARP11. PARP11 knock out and overexpressing A549 cell lines were constructed to evaluate the anti-ZIKV function of PARP11. PARP11 −/− , PARP12 −/− and PARP11 −/− PARP12 −/− HEK293T cell lines were constructed to explain the synergistic effect of PARP11 and PARP12 on NS1 and NS3 protein degradation. Western blotting, immunofluorescence and immunoprecipitation assay were performed to illustrate the interaction between PARP11 and PARP12. Results Both mRNA and protein levels of PARP11 were induced in WT but not IFNAR1 −/− cells in response to IFNα or IFNβ stimulation and ZIKV infection. ZIKV replication was suppressed in cells expressed PARP11 but was enhanced in PARP11 −/− cells. PARP11 suppressed ZIKV independently on itself PARP enzyme activity. PARP11 interacted with PARP12 and promoted PARP12-mediated ZIKV NS1 and NS3 protein degradation. Conclusion We identified ADP-ribosyltransferase PARP11 as an anti-ZIKV ISG and found that it cooperated with PARP12 to enhance ZIKV NS1 and NS3 protein degradation. Our findings have broadened the understanding of the anti-viral function of ADP-ribosyltransferase family members, and provided potential therapeutic targets against viral ZIKV infection.

Keywords